On April 12, 2023 OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, reported a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2023 Annual Meeting being held in Orlando, FL, April 14-19, 2023 (Press release, OncoSpherix, APR 12, 2023, View Source [SID1234630004]). The presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Hypoxia inducible factor (HIF) inhibitor 64B has superior anti-tumor effects compared to tow different tyrosine kinase inhibitors when tested in mouse models of uveal melanoma

Poster: 485/16

Authors: Yang, Grossniklaus, Van Meir, Offermann

Date / Time: April 16, 2023 / 1:30pm to 5:00pm

Location: Section 17